US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Thursday that it has discontinued two Phase 3 clinical trials, KEYNOTE-867 and KEYNOTE-630, based on independent Data Monitoring Committee (DMC) recommendations.
KEYNOTE-867 evaluated KEYTRUDA (pembrolizumab) in combination with stereotactic body radiotherapy (SBRT) for stage I or II non-small cell lung cancer (NSCLC). The DMC recommended discontinuation due to a lack of improvement in event-free survival (EFS) or overall survival (OS) compared to placebo plus SBRT. Additionally, KEYTRUDA in combination with SBRT was associated with higher rates of adverse events (AEs), including AEs leading to death, compared with SBRT and placebo.
KEYNOTE-630 evaluated KEYTRUDA for the adjuvant treatment of high-risk locally advanced cutaneous squamous cell carcinoma (cSCC) following surgery and radiation. The DMC recommended discontinuation due to a lack of statistical significance in recurrence-free survival (RFS). OS was not formally tested, but at the time of the analysis the results did not favour KEYTRUDA compared to placebo. The safety profile of KEYTRUDA in this trial was consistent with its established safety profile.
Merck has informed study investigators and advised patients to discuss next steps with their physicians. Data analyses for both trials are ongoing and will be shared with the scientific community and regulatory agencies.
Biosergen completes first successful BSG005 treatment in invasive fungal trial
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
EydisBio receives USD2.6m SBIR grant from NIH's National Heart, Lung, and Blood Institute
Hyundai Bioscience to conduct Phase 3 trial for high-risk COVID-19 patients
GSK's Nucala approved in Japan for chronic rhinosinusitis with nasal polyps
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
Getinge to acquire Paragonix Technologies
Bridge Biotherapeutics and HitGen sign joint research agreement
Johnson & Johnson receives FDA approval for lung cancer treatment
GSK secures Breakthrough Therapy Designation for lung cancer drug
Phanes Therapeutics' PT217 receives US FDA orphan drug designation
Akeso's ivonescimab supplemental New Drug Application receives Chinese regulator's priority review
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults